Issue 4, 2024

Continuous flow synthesis of the ionizable lipid ALC-0315

Abstract

The ionizable lipid ALC-0315 is the major component of the lipid nanoparticles used to encapsulate the mRNA in the Biontech–Pfizer COVID-19 vaccine. In early 2021, difficulties encountered in scaling up the production and purification of this lipid impeded vaccine manufacturing, leading to delays in vaccination campaigns designed to combat the global coronavirus pandemic. Flow chemistry has impacted synthetic capabilities on all scales. This work describes a proof of principle continuous flow process comprised of four telescoped steps for the production of ALC-0315 with an overall yield of 20% and a productivity of 7 mmol per hour.

Graphical abstract: Continuous flow synthesis of the ionizable lipid ALC-0315

Supplementary files

Article information

Article type
Paper
Submitted
22 nov 2023
Accepted
08 jan 2024
First published
08 jan 2024
This article is Open Access
Creative Commons BY license

React. Chem. Eng., 2024,9, 959-966

Continuous flow synthesis of the ionizable lipid ALC-0315

J. B. Wolf, J. W. Lee, M. B. Plutschack, D. Cambié, A. Seidel-Morgenstern and P. H. Seeberger, React. Chem. Eng., 2024, 9, 959 DOI: 10.1039/D3RE00630A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements